Shanghai Innovation Center of Traditional Chinese Medicine Health Service, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Institute of Digestive Diseases, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Front Endocrinol (Lausanne). 2022 Jul 22;13:885039. doi: 10.3389/fendo.2022.885039. eCollection 2022.
Recent studies have revealed the pivotal role of gut microbiota in the progress of liver diseases including non-alcoholic steatohepatitis (NASH). Many natural herbs, such as (GP), have been extensively applied in the prevention of NASH, while the bioactive components and underlying mechanism remain unclear. The aim of this study was to investigate whether the polysaccharides of GP (GPP) have a protective effect on NASH and to explore the potential mechanism underlying these effects. C57BL/6 male mice were fed with a methionine-choline-deficient (MCD) diet for 4 weeks to induce NASH and administered daily oral gavage of sodium carboxymethylcellulose (CMC-Na), low dose of GPP (LGPP), high dose of GPP (HGPP), and polyene phosphatidylcholine capsules (PPC), compared with the methionine-choline-sufficient (MCS) group. Our results showed that the symptoms of hepatic steatosis, hepatocyte ballooning, liver fibrosis, and oxidative stress could be partially recovered through the intervention of GPP with a dose-dependent effect. Furthermore, gut microbiome sequencing revealed that HGPP altered the composition of gut microbiota, mainly characterized by the enrichment of genera including , , and . Moreover, hepatic transcriptome analysis indicated that the anti-inflammatory effect of HGPP might be associated with toll-like receptor (TLR) and nod-like receptor (NLR) signaling pathways. HGPP could inhibit the expression of TLR2 and downregulate the expression of the NLRP3 inflammasome, as well as the pro-inflammatory cytokine tumor necrosis factor (TNF)-α and interleukin (IL)-1β. In summary, GPP could ameliorate NASH possibly mediated the modulation of gut microbiota and the TLR2/NLRP3 signaling pathway, indicating that GPP could be tested as a prebiotic agent in the prevention of NASH.
最近的研究揭示了肠道微生物群在包括非酒精性脂肪性肝炎(NASH)在内的肝脏疾病进展中的关键作用。许多天然草药,如(GP),已被广泛应用于预防 NASH,但生物活性成分和潜在机制仍不清楚。本研究旨在探讨 GP 的多糖(GPP)是否对 NASH 具有保护作用,并探讨其潜在作用机制。雄性 C57BL/6 小鼠用蛋氨酸-胆碱缺乏(MCD)饮食喂养 4 周,诱导 NASH,并给予羧甲基纤维素钠(CMC-Na)、低剂量 GPP(LGPP)、高剂量 GPP(HGPP)和多烯磷脂酰胆碱胶囊(PPC)每日口服灌胃,与蛋氨酸-胆碱充足(MCS)组相比。我们的结果表明,GPP 的干预可以部分恢复肝脂肪变性、肝细胞气球样变、肝纤维化和氧化应激的症状,具有剂量依赖性。此外,肠道微生物组测序显示,HGPP 改变了肠道微生物群的组成,主要表现为属的丰度增加,包括、和。此外,肝转录组分析表明,HGPP 的抗炎作用可能与 Toll 样受体(TLR)和核苷酸结合寡聚结构域样受体(NLR)信号通路有关。HGPP 可抑制 TLR2 的表达,并下调 NLRP3 炎性体以及促炎细胞因子肿瘤坏死因子(TNF)-α和白细胞介素(IL)-1β的表达。综上所述,GPP 可能通过调节肠道微生物群和 TLR2/NLRP3 信号通路改善 NASH,表明 GPP 可作为预防 NASH 的益生元进行测试。